Anesthesia choice may affect immune system during breast cancer surgery
NCT ID NCT07648810
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will enroll 56 women with breast cancer to see if two different regional anesthesia techniques (paravertebral block vs. erector spinae plane block) cause different immune responses during surgery. Participants will receive one of the two blocks along with general anesthesia using propofol. Blood samples will be taken before surgery and at 24 and 48 hours after to measure immune markers. The goal is to find which method may be less disruptive to the immune system.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- regional anesthetic injection (paravertebral block or erector spinae plane block) with propofol general anesthesia
- What this could lead to
- If it works, this could help doctors choose an anesthesia method that causes less immune disruption during breast cancer surgery.
- What could go wrong
- This is a small, early-stage study (56 participants) that only measures immune markers, not long-term outcomes. Results may not change practice or apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 56 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * ASA I and ASA II status, normal BMI Exclusion Criteria: * ASA III and ASA IV status, coagulopathy, chronic opioid use, diabetes, local infection of the skin
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- Can a tiny clip spare breast cancer patients full lymph node removal?
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?